Novartis files for approval of glycopyrronium bromide for COPD in Japan
This article was originally published in Scrip
Executive Summary
Novartis has filed for Japanese approval of its chronic obstructive pulmonary disease (COPD) treatment, NVA237 (glycopyrronium bromide), its partner, Vectura has reported.